Hillhurst Biopharmaceuticals
Hillhurst Bio is a clinical-stage company developing novel oral liquid drugs, using its proprietary GLASS platform to enable the oral delivery of medicines that previously could only be delivered by inhalation. Our lead drug product, HBI-002, targets the treatment of sickle cell disease and Parkinson’s disease, and our follow-on non-opioid drug, HBI-201, targets acute pain.
Contact Name:
Andrew Gomperts
Contact Email:
Website:
https://hillhurstbio.com
City, State – Congressional District:
Montrose,
CA
–
28
Technology:
Drug
Funding:
Allergy and Infectious Diseases (NIAID),
Diabetes, Digestive, and Kidney (NIDDK),
Eye (NEI),
General Medical (NIGMS),
Heart, Lung, and Blood (NHLBI),
Neurological Disorders and Stroke (NINDS)
NIH Projects:
NIH RePorter for
Hillhurst Biopharmaceuticals
Sponsored Event(s):
BIO | 2022
,
Life Sciences Summit | 2021
,
BIO | 2024
